A Unique Micropeptides Discovery Platform: Shining Light on the Dark Proteome
At EIRNABio, we have developed the Translon Explorer platform to uncovering the vast, uncharted world of small proteins with significant biological functions. These previously overlooked small proteins, often translated from non-coding RNAs or small open reading frames (sORFs), are emerging as key regulators in cellular processes, disease mechanisms, and therapeutic innovation.
Why Focus on Micropeptides?
For decades, research has focused on large, well-characterized proteins. However, advancements in ribosome profiling and translatomics have revealed that many functional microproteins remain hidden within the genome, influencing pathways in cancer, neurodegeneration, and immune regulation. Translon Explorer enables systematic identification and characterization of these molecules, unlocking new opportunities for drug development and biomarker discovery.
- Leveraging advanced ribosome profiling data analysis to pinpoint translons that yield micropeptides.
- Therapeutic Potential: Can be used as the basis to explore novel druggable targets and micropeptide-based therapeutics.
- Cross-Disciplinary Applications: Spanning oncology, rare diseases, regenerative medicine, and immunotherapy.
The drug discovery landscape
By harnessing the power of Translon Explorer, researchers can expand the drug discovery landscape, uncover novel mechanisms of disease, and open new frontiers in precision medicine.
Schedule a discussion on Translon Explorer